Q4 2022 Trevena Inc Earnings Call Transcript
Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Barry Shin, Chief Financial Officer for Trevena. Thank you. You may begin.
Great. Thanks. Good morning, and welcome, everyone. With me today are Carrie Bourdow, our President and CEO; Patty Drake, our Chief Commercial Officer; and our Chief Medical Officer, Mark Demitrack.
As a reminder, OLINVYK was approved by the FDA in August 2020 and contains oliceridine, an opioid, which is a schedule II controlled substance with a high potential for abuse similar to other opioids is indicated in adults for the management of acute pains fair enough to require an IV opioid analgesic entered from alternative treatments are inadequate.
As with all opioids, serious life-threatening or fatal respiratory depression may occur in patients treated with OLINVYK as indicated in the boxed warning.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
